# Pucotenlimab Combined With Lenvatinib as a Neodjuvant Therapy for Non Clear Cell Renal Cell Carcinoma

> **NCT06129955** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 47 (estimated)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **DRUG:** Pucotenlimab Combined With Lenvatinib

## Key facts

- **NCT ID:** NCT06129955
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-11-11
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 47 (ESTIMATED)
- **Last updated:** 2023-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06129955

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06129955, "Pucotenlimab Combined With Lenvatinib as a Neodjuvant Therapy for Non Clear Cell Renal Cell Carcinoma". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT06129955. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*